Alexion Pharma (ALXN) Tops Q4 EPS by 32c, FY EPS Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharmaceuticals (ALXN) PT Lowered to $165 at RBC Capital
February 5, 2019 6:42 AM ESTRBC Capital analyst Kennen MacKay lowered the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $165.00 (from $170.00) while maintaining a Outperform rating.
MacKay commented, "We came away from ALXNs Q4:18 call excited by detail into a growing pipeline stable and increasing confidence that... More
